Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
James M. Martinez(Baylor College of Medicine), Sandra Garcês(Amgen (United States)), Nada Hindiyeh(Stanford University), Michael E. Hodsdon(Eli Lilly (United States)), Greg Anglin(Eli Lilly (Canada)), Eric Pearlman(University of California, San Francisco), Kavita Kalidas(University of South Florida), William Kielbasa(Eli Lilly (United States)), Brian A. Moser(Eli Lilly (United States))
Cited by 14
Related Papers
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532
N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis
|Nature Communications|2020|453
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
|Nature Communications|2016|446